People who experience psychosis may produce too much or even too little cannabinoids (from overactive dopamine receptors). CBD is milder than our internal cannabinoids and helps to re-establish a balance of cannabinoids in the brain. CBD also helps lower inflammation, which is often increased in schizophrenia. THC, on the other hand, is stronger than our internal cannabinoids (anandamide and 2-AG), this way potentially triggering psychosis [46, 48].
Like we said, once you start using CBD oil more frequently and are able to gauge how much you need to find relief or therapy, then you can jump up to the more high-potency products as needed. For reference, doses will typically range anywhere from 5 mg to 100+ mg in a single day. And for epilepsy patients, they may take anywhere between 300 mg to an entire gram (1,000 mg) per dose — or more!
Vape Pens – Perhaps the easiest way to get the CBD Oil into your body is through a vape pen. A vape pen is about the size of an ink pen but has a CBD oil cartridge with a heating element. Many people like vape pens because there is very little in the way of odor after using it and it allows for a lot of discretion because it can be pulled out of your pocket and used on demand.
There are likely very complex relationships also occurring between various Cannabinoids in Cannabis that may lead to certain medical efficacy. That is important to remember when considering the consumption of products that contain Cannabinoids. There is an attractiveness to isolating a specific chemical, researching it, patenting synthetic derivatives, and marketing specific drugs. That said, the relationships are complex, will likely take years to understand, and many patients I’ve met appear to find the most medical benefit from a diverse group of Cannabinoids whose interactions are not particularly well understand, but the results are hard to argue with.
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.
CBD works by attaching itself to specific receptors of the body’s own endocannabinoid system. The human body is known to produce cannabinoids of its own, which affect the cannabinoid receptors CB1 and CB2. The CB1 receptors are generally found in the brain, and deal with pain, mood and emotions, movement, appetite, among others. THC acts upon the CB1 receptors. Meanwhile, CB2 receptors are more commonly found throughout the immune system, affecting inflammation and thus pain. CBD is thought to act upon these receptors, by influencing the body to produce its own cannabinoids in order to rebalance itself.
Also listed among our low potency products is our bestselling CanChew® gum. With just 10 mg of CBD per piece of gum, it is easy to get started with CBD as a supplement, and adding more CBD to your diet is as simple as chewing another piece of gum. Another approachable product for those just starting out with CBD, CanChew® gum is a simple delivery method for getting your daily CBD.